Search This Blog

Wednesday, October 30, 2024

Neurocrine Q3 Results, Raises 2024 INGREZZA Sales Guidance

 INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth

INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion

Board Authorizes $300 Million Share Repurchase Plan

https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-third-quarter-2024-financial-results-and-raises-2024-ingrezza-sales-guidance-302290962.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.